KAPA (Kairos Pharma) Total Stockholders Equity : $4.78 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Kairos Pharma Total Stockholders Equity?

Kairos Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $4.78 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Kairos Pharma's Book Value per Share for the quarter that ended in Dec. 2024 was $0.35. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Kairos Pharma's Debt-to-Equity for the quarter that ended in Dec. 2024 was 0.00.

Kairos Pharma Total Stockholders Equity Historical Data

The historical data trend for Kairos Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kairos Pharma Total Stockholders Equity Chart

Kairos Pharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Total Stockholders Equity

-0.34

-1.17

-1.18

-2.08

4.78

Kairos Pharma Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Stockholders Equity	Get a 7-Day Free Trial									-2.08	-0.92	-0.89	3.33	4.78

Kairos Pharma (AMEX:KAPA) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Kairos Pharma's Book Value per Share for the quarter that ended in Dec. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(4.776	-	0)	/	13.737
	=	0.35

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Kairos Pharma's Debt-to-Equity for the quarter that ended in Dec. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	4.776
	=	0.00

Kairos Pharma Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Kairos Pharma's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Kairos Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kairos Pharma Ltd (AMEX:KAPA) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2355 Westwood Boulevard, 139, Los Angeles, CA, USA, 90064

Website

https://kairospharma.com

Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.